8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 11, 2026·SEC
Foghorn Therapeutics Inc.(FHTX)Earnings, Financials & Key Ratios
FHTX•NASDAQ
$4.03
Price updated Jun 25, 2026
AboutFoghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$31M+36.8%
- EBITDA-$79M+20.9%
- Net Income-$74M+14.2%
- EPS (Diluted)-1.18+25.3%
- Gross Margin89.22%-10.8%
- EBITDA Margin-254.86%+42.1%
- Operating Margin-265.64%+41.5%
- Net Margin-240.33%+37.3%
FHTX Price & Volume
Foghorn Therapeutics Inc. (FHTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Milestone Dependency Strains Capital Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical milestone funding dependency
"Foghorn Therapeutics faces a challenging outlook defined by high R&D intensity and a reliance on volatile, milestone-driven revenue that fails to cover its $20 million average quarterly operating loss. While the Gene Traffic Control platform remains the core value driver, the company's negative equity position of $76.4 million as of 2026Q1 and persistent cash burn necessitate careful monitoring of future capital raises. Investors should remain cautious as the firm's inability to achieve self-sustaining operations through its current partnership model creates significant long-term execution risk."
Verdict Logic
the company's reliance on external funding is underscored by a narrowing cash position of $88.9 million against a consistent quarterly burn rate that threatens long-term solvency.
FHTX Growth Metrics
Foghorn Therapeutics Inc. (FHTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years135.14%
3 Years17.14%
TTM20.08%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.6%
Return on Capital
10 Years-64.44%
5 Years-37.36%
3 Years-43.27%
Last Year-46.21%
FHTX Recent Earnings
Foghorn Therapeutics Inc. (FHTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 3/12 qtrs (25%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.29-3.6%
$0.28
Rev
$3M-58.9%
$8M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.34-21.4%
$0.28
Rev
$9M-8.9%
$10M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.25+19.4%
$0.31
Rev
$8M-14.2%
$9M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.28+9.7%
$0.31
Rev
$8M-7.5%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.29vs $0.28-3.6% | $3Mvs $8M-58.9% |
| Q2 2026 | Mar 11, 2026 | $0.34vs $0.28-21.4% | $9Mvs $10M-8.9% |
| Q4 2025 | Nov 5, 2025 | $0.25vs $0.31+19.4% | $8Mvs $9M-14.2% |
| Q3 2025 | Aug 5, 2025 | $0.28vs $0.31+9.7% | $8Mvs $8M-7.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Foghorn Therapeutics Inc. (FHTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.03 | $236.62M | -3.42 | 36.75% | -240.33% | — | — | |
| $178.17 | $37.88B | -29.94 | — | — | -83.22% | — | |
| $30.14 | $3.5B | -34.64 | 48.29% | -188.15% | -41.54% | — | |
| $0.65 | $27.87M | -1.05 | 13.77% | -4726.21% | -69.57% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $17.55 | $2.26B | 8.48 | 20.38% | 99.97% | 64.48% | — |
Compare FHTX vs Peers
Foghorn Therapeutics Inc. (FHTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FHTX SEC Filings & Documents
Foghorn Therapeutics Inc. (FHTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when FHTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FHTX Frequently Asked Questions
Foghorn Therapeutics Inc. (FHTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Foghorn Therapeutics Inc.'s revenue?
Foghorn Therapeutics Inc. (FHTX) reported $28.2M in revenue for fiscal year 2025.
How fast is Foghorn Therapeutics Inc. growing?
Foghorn Therapeutics Inc. (FHTX) grew revenue by 36.8% over the past year. This is strong growth.
Is FHTX profitable?
Foghorn Therapeutics Inc. (FHTX) reported a net loss of $75.3M for fiscal year 2025.
Dividend & Returns
What is Foghorn Therapeutics Inc.'s free cash flow?
Foghorn Therapeutics Inc. (FHTX) had negative free cash flow of $87.4M in fiscal year 2025, likely due to heavy capital investments.